PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR in the treatment of patients with locally advanced unresectable pancreatic cancer.

Trial Details

NCT ID
NCT06359275
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • PD-1
  • Nab-paclitaxel
  • Gemcitabine
  • PULSAR
Locations (sample)
  • Shanhai, China|31.14019,121.06417

Key Eligibility Criteria

  • Sign the informed consent form. The subject has received a full explanation and understanding of the purpose, content, predicted efficacy, pharmaco…
  • Target group
  • Locally advanced pancreatic adenocarcinoma confirmed by histopathology or cytology, or pancreatic cancer with only local recurrence but no distant …
  • There is at least one measurable objective lesion according to RECIST1.1 standards;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →